It seems demand is growing amongst women in perimenopause, menopause and postmenopause looking for multifaceted weight loss ...

But the newest study that has gone viral is an even more impressive outcome. Headlines are claiming that researchers have ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that the off-label use of semaglutide and ...

The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Researchers analysed data from 150 adults with T1D, divided into semaglutide, tirzepatide, and control groups.

Cratos Health is a wellness center designed to improve your mental and physical well-being. Whether you’re looking for ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.